Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Fabhalta

(Rimiducid)

Phase 2Small molecule

BBellicum Pharmaceuticals

Rimiducid is used to treat a rare blood disorder called hereditary angioedema, which causes sudden swelling in various parts of the body. It helps prevent these painful and potentially dangerous swelling episodes.[1] Fabhalta is currently being investigated across 8 indications[3], with its most advanced program in Phase 2.[1]

Fabhalta is one of 269 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 2.

8

Indications

23

Total Trials

12

Active Trials

268

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Salivary Gland CancerActive, not recruiting

Uveal MelanomaActive, not recruiting

Hematopoietic and Lymphoid Cell NeoplasmActive, not recruiting

Colorectal CancerActive, not recruiting

Prostate CancerActive, not recruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

Multiple MyelomaActive, not recruiting

Systemic Lupus ErythematosusPhase 1

Active, not recruiting

Salivary Gland CancerPhase 1

Active, not recruiting

Uveal MelanomaPhase 1/Phase 2

Active, not recruiting

Hematopoietic and Lymphoid Cell NeoplasmPhase 1

Active, not recruiting

Colorectal CancerPhase 1

Active, not recruiting

Prostate CancerPhase 1

Active, not recruiting

Diffuse Large B-Cell LymphomaPhase 2

Active, not recruiting

Multiple MyelomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Fabhalta

BBellicum Pharmaceuticals

Novantrone

Mekinist

Trexall

Alnylam Pharmaceuticals

Duragesic

Ranexa

MMenarini International Operations Luxembourg SA

Prednisone/prednisolone

Triptorelin Pamoate

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Xylocaine

MMEDRx USA, Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1Recruiting

Colorectal Cancer

NCT06358430

Q4 2032

Phase 1/2Active, not recruiting

Stem Cell Transplant

NCT01744223

Q1 2033

Phase 1Active, not recruiting

Recurrent Disease

NCT02477878

Q3 2033

Phase 2Not yet recruiting

Diffuse Large B-Cell Lymphoma

NCT07164469

Clinical

Trials by Indication[1]

Stem Cell Transplant4 trials

Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

Active, not recruiting·BBellicum Pharmaceuticals·Phase 1/2·NCT03301168·120 enrolled

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

Active, not recruiting·BBellicum Pharmaceuticals·Phase 1/2·NCT01744223·36 enrolled

Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant

Withdrawn·FFred Hutchinson Cancer Center·Phase 1·NCT03807063

Show 1 more trial

Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant

Terminated·BBellicum Pharmaceuticals·Phase 1/2·NCT02065869·187 enrolled

Multiple Myeloma3 trials

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

Recruiting·PPoseida Therapeutics, Inc.·Phase 1·NCT04960579·275 enrolled

T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT03958656·13 enrolled

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

Terminated·PPoseida Therapeutics, Inc.·Phase 1/2·NCT03288493·105 enrolled

Recurrent Disease1 trial

Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant

Active, not recruiting·BBellicum Pharmaceuticals·Phase 1·NCT02477878·10 enrolled

Malignancies1 trial

Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant

Active, not recruiting·BBellicum Pharmaceuticals·Phase 1·NCT03459170·15 enrolled

Selected Advanced Solid Tumors1 trial

Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Terminated· Regeneron logo

Regeneron·Phase 1·NCT02744287·52 enrolled

13 more indications

Patients With Advanced Solid Tumors1 trial

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06066424·54 enrolled

Relapsed/Refractory1 trial

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

Active, not recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1/2·NCT03016377·17 enrolled

Post Stem Cell Transplant1 trial

BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study

No longer available·BBellicum Pharmaceuticals··NCT03639844

B-cell Malignancies1 trial

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

Recruiting·PPoseida Therapeutics, Inc.·Phase 1·NCT06014762·120 enrolled

Salivary Gland Cancer1 trial

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Terminated·PPoseida Therapeutics, Inc.·Phase 1·NCT04249947·40 enrolled

Advanced or Metastatic Solid Tumors1 trial

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

Active, not recruiting·PPoseida Therapeutics, Inc.·Phase 1·NCT05239143·180 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07164469·100 enrolled

Colorectal Cancer1 trial

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06358430·42 enrolled

Hematologic Malignancies1 trial

Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT

Withdrawn·BBellicum Pharmaceuticals·Phase 1·NCT02786485

Uveal Melanoma1 trial

Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma

Terminated·BBellicum Pharmaceuticals·Phase 1/2·NCT02743611·4 enrolled

HSCT1 trial

Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS

Terminated·BBellicum Pharmaceuticals·Phase 2/3·NCT03699475·1 enrolled

Systemic Lupus Erythematosus1 trial

A Phase I, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Patients With Severe, Treatment-refractory Systemic Lupus Erythematosus

Not yet recruiting· Roche logo

Roche·Phase 1·NCT06984341·162 enrolled

Unspecified1 trial

Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study

Terminated·BBellicum Pharmaceuticals·Phase 1/2·NCT03733249·187 enrolled

Sources

References

[1]
ClinicalTrials.gov — 23 trial records for Rimiducid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rimiducid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rimiducid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bellicum Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBellicum Pharmaceuticals

Related News